NCLT approves Sequent Scientific and Viyash merger worth ₹8,000 crore
pre-market1 source ↓written by the desknot a recommendation
- between Sequent Scientific
- ₹8,000 crore merger
- in FY 2023-24
- ₹100 crore
- while Viyash
- ₹150 crore
- of Sequent's shareholders
- 99.98%
The National Company Law Tribunal (NCLT) has approved the ₹8,000 crore merger between Sequent Scientific and Viyash Life Sciences. Sequent reported operating profits of ₹100 crore in FY 2023-24, while Viyash had ₹150 crore. This merger, supported by 99.98% of Sequent's shareholders, aims to leverage back-end synergies.
Not investment advice. For informational purposes only.